AGM 2020 Presentation

November 18, 2020August 16, 2022 Alterity Therapeutics

2020

Post navigation

Target Market Determination – Placement Offer
Target Market Determination – Broker Offer
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2020 Presentation

Related Posts

Completion of investment by Life Biosciences LLC and capital raising update

FDA Approval to Commence Huntington’s Disease Clinical Trial Using Prana’s PBT2: Huntington Study Group appointed to coordinate the trial and start recruitment

Notice of General Meeting 2019